Liver Cancer Risk Linked to Faulty Cysteine Metabolism Through METTL14 Gene
Scientists discover how a key RNA-modifying enzyme controls antioxidant defenses in the liver, with major implications for NAFLD and liver cancer.
Summary
Researchers at Sichuan Provincial People's Hospital used a mouse model with liver-specific deletion of METTL14 — an enzyme that adds m6A methylation marks to RNA — to study how this affects fatty liver disease and liver cancer. They found that losing METTL14 reduces methylation of SLC7A11 mRNA, a transporter responsible for importing cystine into cells. Without sufficient cystine uptake, cells cannot synthesize glutathione (GSH), the body's primary antioxidant. This leads to oxidative stress, mitochondrial damage, lipid peroxidation, and cell death, accelerating both NAFLD and diethylnitrosamine-induced hepatocellular carcinoma. The study identifies the METTL14-SLC7A11-cysteine-GSH axis as a novel therapeutic target for these serious liver conditions.
Detailed Summary
Non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) are two of the most pressing liver health crises globally, driven in part by modern dietary patterns and metabolic dysfunction. Understanding the molecular mechanisms linking metabolic reprogramming to disease progression is essential for developing new treatments. This study focuses on a newly identified regulatory axis connecting RNA epigenetics to cysteine metabolism and antioxidant defense.
The research team employed a hepatocyte-specific METTL14 knockout mouse model — meaning the gene was deleted only in liver cells — to investigate how this RNA methyltransferase shapes amino acid metabolism during NAFLD. METTL14 is responsible for depositing N6-methyladenosine (m6A) marks on messenger RNA, a modification known to regulate mRNA stability, translation, and splicing across many biological processes.
Key findings showed that ablating METTL14 reduces m6A methylation on SLC7A11 mRNA, impairing the function of this critical cystine/glutamate transporter. Reduced cystine import directly compromises the cell's ability to synthesize glutathione (GSH), the master cellular antioxidant. Downstream consequences include mitochondrial structural and functional damage, accumulation of reactive oxygen species (ROS), enhanced lipid peroxidation, and increased hepatocyte death — all hallmarks of NAFLD and HCC progression.
The study also used diethylnitrosamine to chemically induce HCC in the mouse model, demonstrating that METTL14 loss accelerates tumor development, further cementing the axis's oncogenic relevance.
These findings suggest that the METTL14-SLC7A11-cysteine-GSH pathway is a druggable axis. Therapeutically restoring cystine uptake or boosting GSH synthesis in patients with reduced METTL14 activity could slow liver disease progression. However, all data derive from mouse models, and clinical translation requires validation in human tissues and trials.
Key Findings
- METTL14 deletion in hepatocytes reduces m6A methylation on SLC7A11 mRNA, impairing cystine uptake.
- Impaired cystine import disrupts glutathione synthesis, causing oxidative stress and lipid peroxidation.
- METTL14 loss causes mitochondrial structural damage and functional decline in liver cells.
- Hepatocyte-specific METTL14 knockout accelerates both NAFLD progression and chemically induced HCC in mice.
- METTL14-SLC7A11-cysteine-GSH axis is proposed as a novel therapeutic target for liver disease.
Methodology
The study used a hepatocyte-specific METTL14 knockout mouse model to examine liver amino acid metabolic profiles during NAFLD. Hepatocellular carcinoma was induced chemically using diethylnitrosamine (DEN). Investigators assessed m6A methylation status, SLC7A11 expression, GSH levels, ROS accumulation, lipid peroxidation, and mitochondrial integrity.
Study Limitations
All experimental data are derived from mouse models, limiting direct clinical applicability without human validation. The abstract does not detail whether METTL14 or SLC7A11 expression levels were measured in human NAFLD or HCC tissue samples. The causal directionality in human disease contexts and the safety of targeting this axis therapeutically remain unestablished.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: